USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 8, 2022 | Jun 2022 | $-0.63 | - | $-0.60 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 8, 2022 | Jun 2022 | $3.95M | - | $4.38M |
Fulcrum Therapeutics's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Jun 2022 | 7 | $-0.63 | $-0.67 | $-0.56 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 8 | $-2.52 | $-3.10 | $-2.06 |
| Dec 2023 | 8 | $-2.69 | $-3.35 | $-1.86 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Jun 2022 | 1 / 0 | $-0.65 | $-0.62 | $-0.62 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 4 / 0 | $-2.72 | $-2.66 | $-2.56 |
| Dec 2023 | 2 / 0 | $-2.89 | $-2.99 | $-2.73 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Jun 2022 | 7 | $3.95M | $2.00M | $5.16M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 8 | $14.25M | $0.00 | $20.74M |
| Dec 2023 | 8 | $14.18M | $0.00 | $20.95M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 4, 2022 | Mar 2022 | $-0.61 | - | - |
| Mar 3, 2022 | Dec 2021 | $-0.73 | $-0.58 | 20.55% |
| Nov 4, 2021 | Sep 2021 | $-0.65 | $-0.57 | 11.91% |
| Aug 10, 2021 | Jun 2021 | $-0.65 | $-0.60 | 8.10% |
| May 6, 2021 | Mar 2021 | $-0.66 | $-0.54 | 17.77% |
| Mar 4, 2021 | Dec 2020 | $-0.73 | $-0.63 | 13.10% |
| Nov 10, 2020 | Sep 2020 | $-0.64 | $-0.70 | -9.80% |
| Aug 11, 2020 | Jun 2020 | $-0.75 | $-0.66 | 11.61% |
| May 13, 2020 | Mar 2020 | $-0.76 | $-0.81 | -6.58% |
| Mar 5, 2020 | Dec 2019 | $-0.88 | $-0.71 | 19.62% |
| Nov 14, 2019 | Sep 2019 | $-0.72 | $-0.97 | -34.72% |
| Aug 26, 2019 | Jun 2019 | $-0.75 | $-0.71 | 5.33% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 3, 2022 | Dec 2021 | $-2.38 | $-2.29 | - |
| Mar 4, 2021 | Dec 2020 | $-2.88 | $-2.80 | - |
| Mar 5, 2020 | Dec 2019 | $-4.03 | $-2.39 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 4, 2022 | Mar 2022 | $3.94M | - | - |
| Mar 3, 2022 | Dec 2021 | $2.68M | $5.06M | 1.89% |
| Nov 4, 2021 | Sep 2021 | $2.25M | $4.93M | 2.19% |
| Aug 10, 2021 | Jun 2021 | $1.60M | $4.38M | 2.74% |
| May 6, 2021 | Mar 2021 | $1.42M | $4.79M | 3.37% |
| Mar 4, 2021 | Dec 2020 | $1.31M | $4.22M | 3.23% |
| Nov 10, 2020 | Sep 2020 | $550.00K | $1.85M | 3.36% |
| Aug 11, 2020 | Jun 2020 | $0.00 | $2.00M | - |
| May 13, 2020 | Mar 2020 | $0.00 | $750.00K | - |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 14, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 26, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 3, 2022 | Dec 2021 | $14.39M | $19.16M | 33.17% |
| Mar 4, 2021 | Dec 2020 | $5.69M | $8.82M | 55.06% |
| Mar 5, 2020 | Dec 2019 | $0.00 | $0.00 | - |
FULC's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Fulcrum Therapeutics's next quarterly earnings is $-0.63, with a low EPS estimation of $-0.67, and a high estimation of $-0.56.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.65, the last 2 month trend is $-0.62, and the 3 month trend is $-0.62.
Based on analysts, the average revenue estimation is $3.95M, with a low revenue estimation of $2.00M, and a high estimation of $5.16M.
Fulcrum Therapeutics's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.
Fulcrum Therapeutics's previous annual earnings date was Mar 3, 2022 for its fiscal year ended Dec 31, 2021.
FULC's earnings per share (EPS) was $-2.29, beating the consensus analysts forecast of $-2.38 by -3.78% , and higher than the previous year's EPS (Dec 2020) by -18.21%.
Revenues were $19.16M, better than the forecast of $14.39M by 33.17%, and up by 117.19% from previous year's revenue.
The company reported a net income of $-80.85M.
Fulcrum Therapeutics reported a free cash flow of $-80.19M for its fiscal year, compared to $-55.00M a year ago.
The company ended the fiscal year with $469.00K in total debt, an increase of 2658.82% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
